Childhood obesity is a formidable public health challenge in the US, posing a risk of various downstream health issues for ...

Early results from Wave's ongoing DMD Phase II trial saw a decline in muscle necrosis and inflammation in the trial ...

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Acumen Pharmaceuticals has concluded enrolment for the Phase II ALTITUDE-AD trial of sabirnetug for treating patients with ...

Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...

Lipocine has announced the commencement of a Phase III clinical trial of LPCN 1154, being developed for postpartum depression ...

J&J's Rybrevant and Lazcluze combination reduced the risk of death by 25% compared to AstraZeneca’s Tagrisso in NSCLC.

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

The randomised trial saw more than half of patients dosed with Sunosi achieving clinical response to the therapy used to ...

Helicore Biopharma has dosed the first subject in the randomised first-in-human Phase I trial of HCR-188 to treat obesity.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...